|
[1] WHO. Hepatitis B fact sheets[EB/OL].(2019-07-19)[2019-07-01]. Http://www. who. Int/news-room/fact-sheets/detail/hepatitis-b.
|
|
[2] Polaris Observatory Collaborators. Global prevalence,treatment,and prevention of hepatitis B virus infection in 2016:A modellingstudy[J]. Lancet Gastroenterol Hepatol,2018,3(6):383-403.
|
|
[3] ZHAO H. The epidemiology of hepatitis B virus infection in China[J]. J Viral Hepat,2018,25(12):1624.
|
|
[4] YUE MF,CHEN DS,GEOFFREY M,et al. Hepatitis B virus infection[J]. Nat Rev Dis Primers,2018,4:18036.
|
|
[5] JIANG FM,CHENG SQ. Expression and clinical significance of Toll-like receptors 3 and 4 in patients with chronic hepatitis B[J]. Int J Virol,2017,24(3):209-212.(in Chinese)蒋福明，程书权．慢性乙型肝炎患者Toll样受体3、4的表达及其临床意义[J]．国际病毒学杂志，2017,24(3):209-212.
|
|
[6] PEERIDOGAHEH H,MESHKAT Z,HABIBZADEH S,et al. Current concepts on immunopathogenesis of hepatitis B virus infection[J]. Virus Res,2018,245:29-43.
|
|
[7] TSENG TC,HUANG LR. Immunopathogenesis of hepatitis B virus[J]. J Infect Dis,2017,216(S8):s765-s770.
|
|
[8] ZHAO YM,GAO MD,SUN JP,et al. Research progress of depleted CD8+T cells[J]. Int J Virol,2019,26(2):139-142.(in Chinese)赵亚楠，高梦丹，孙坚萍，等．耗竭型CD8+T细胞的研究进展[J]．国际病毒学杂志，2019,26(2):139-142.
|
|
[9] BERTOLETTI A,le BERT N. Immunotherapy for chronic hepatitis B virus infection[J]. Gut Liver,2018,12(5):497-507.
|
|
[10] WALSH R,HAMMOND R,JACKSON K,et al. Effects of SB9200(Inarigivir)therapy on immune responses in patients with chronic hepatitis B[J]. J Hepatol,2018,68(S1):s89.
|
|
[11] YUEN M,CHEN C,LIU C,et al. Ascending dose cohort study of inarigivir-a novel RIG I agonist in chronic HBV patients:Final results of the ACHIEVE trial[J]. J Hepatol,2019,70(S1):e47-e48.
|
|
[12] COLLEDGE D,JACKSON K,SOZZI V,et al. The novel antiviral agent inarigivir inhibits both nucleos(t)ide analogue and capsid assembly inhibitor resistant HBV in vitro[J]. J Hepatol,2019,70(S1):e476-e477.
|
|
[13] NIU C,LI L,DAFFIS S,et al. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism[J]. J Hepatol,2018,68(5):922-931.
|
|
[14] AGARWAL K,AHN SH,ELKHASHAB M,et al. Safety and efficacy of vesatolimod(GS-9620)in patients with chronic hepatitis B who are not currently on antiviral treatment[J]. J Viral Hepat,2018,25(11):1331-1340.
|
|
[15] HERSCHKE F,LI C,de CREUS A,et al. Antiviral activity of JNJ-4964(AL-034/TQ-A3334),a selective toll-like receptor 7 agonist,in AAV/HBV mice after oral administration for12 weeks[J]. J Hepatol,2019,70(S1):e49-e50.
|
|
[16] DAFFIS S,CHAMBERLAIN J,ZHENG J,et al. Sustained efficacy and surface antigen seroconversion in the woodchuck model of chronic hepatitis B with the selective tolllike receptor 8agonist GS-9688[J]. J Hepatol,2017,66(1):s692-s693.
|
|
[17] AMIN OE,COLBECK E,DAFFIS S,et al. In vitro modulation by TLR8 agonist GS-9688 of multiple regulatory cell types in patients with chronic hepatitis B[J]. J Hepatol,2019,70(S1):e445-e446.
|
|
[18] TIO M,RAI R,EZEOKE OM,et al. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant,HIV or hepatitis B/C infection[J]. Eur J Cancer,2018,104:137-144.
|
|
[19] ZHANG F,WEI H,WANG X,et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade[J]. Cell Discov,2017,3:17004.
|
|
[20] ALI R,SINGH S,HAQ W. IAP proteins antagonist:an introduction and chemistry of smac mimetics under clinical development[J]. Curr Med Chem,2018,25(31):3768-3795.
|
|
[21] PAN W,LUO Q,YAN X,et al. A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunity[J]. Biochem Pharmacol,2018,154:127-135.
|
|
[22] KAH J,KOH S,VOLZ T,et al. Lymphocytes transiently expressing virus-specific T cell receptors reducehepatitis B virus infection[J]. J Clin Invest,2017,127(8):3177-3188.
|
|
[23] KRUSE RL,SHUM T,TASHIRO H,et al. HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liverchimeric mice[J]. Cytotherapy,2018,20(5):697-705.
|
|
[24] WISSKIRCHEN K,METZGER K,SCHREIBER S,et al. Isolation and functional characterization of hepatitis B virus-specific T-cellreceptors as new tools for experimental and clinical use[J]. PLo S One,2017,12(8):e0182936.
|
|
[25] LUCIFORA J,XIA Y,REISINGER F,et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA[J]. Science,2014,343(6176):1221-1228.
|
|
[26] MEIER MA,SUSLOV A,KETTERER S,et al. Hepatitis B virus covalently closed circular DNA homeostasis is independent of the lymphotoxin pathway during chronic HBV infection[J]. J Viral Hepat,2017,24(8):662-671.
|
|
[27] MARTIN P,DUBOIS C,JACQUIER E,et al. TG1050,an immunotherapeutic to treat chronic hepatitis B,induces robust T cells and exerts an antiviral effect in HBV-persistent mice[J]. Gut,2015,64(12):1961-1971.
|
|
[28] KRATZER R,SANSAS B,LLU K,et al. A meta-analysis of the antiviral activity of the HBV-specific immunotherapeutic TG1050 confirms its value over a wide range of HBsAg levels in a persistent HBV pre-clinical model[J]. Hum Vaccin Immunother,2018,14(6):1417-1422.
|
|
[29] PAULSEN D,WEBER O,RUEBSAMEN SH. AIC649 induces a bi-phasic treatment response in the woodchuck model of chronic hepatitis B[J]. PLo S One,2015,10(12):e0144383.
|
|
[30] ADDY I,JAMBRECINA A,BERG T,et al. First in human,single ascending dose clinical trial of AIC649 in patients with chronic hepatitis[J]. J Hepatol,2019,70(S1):e478-e479.
|
|
[31] Inovio’s news and media. Inovio’s DNA immunotherapy demonstrates immune response results key in treating chronic hepatitis B infection[EB/OL].(2018-03-04)[2019-07-01].http://ir. inovio. com/news-and-media/news/press-release-details/2018/Inovios-DNA-Immunotherapy-Demonstrates-Immune-Response-Results-Key-in-Treating-Chronic-Hepatitis-B-Infection.
|
|
[32] TANG L,CHEN C,GAO X,et al. Interleukin 21 reinvigorates the antiviral activity of hepatitis B virus(HBV)-specific CD8+T cells in chronic HBV infection[J]. J Infect Dis,2019,219(5):750-759.
|
|
[33] WANG X,XU ZQ,FU JJ,et al. Role of interleukin-21 and interleukin-21 receptor polymorphisms in the treatment of HBe Ag-positive chronic hepatitis B patients with peginterferon[J]. Medicine(Baltimore),2018,97(23):e10891.
|
|
[34] SHEN Z,YANG H,YANG S,et al. Hepatitis B virus persistence in mice reveals IL-21 and IL-33 as regulators of viral clearance[J]. Nat Commun,2017,8(1):2119.
|
|
[35] ZENG Z,KONG X,LI F,et al. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier[J]. J Immunol,2013,191(8):4184-4193.
|
|
[36] RIGOPOULOU EI,SURI D,CHOKSHI S,et al. Lamivudine plus interleukin-12 combinationtherapy in chronic hepatitis B:Antiviral and immunological activity[J]. Hepatology,2005,42(5):1028-1036.
|
|
[37] SCHIRDEWAHN T,GRABOWSKI J,OWUSU SEKYERE S,et al. The third signal cytokine interleukin 12 rather than immune checkpoint inhibitors contributes to the functional restoration of hepatitis D virus-specific T cells[J]. J Infect Dis,2017,215(1):139-149.
|
DownLoad: